

Sativa Group PLC

08:27 02 Apr 2019

Sativa Investments teams up with King's College London to research cannabinoids for medicinal use

UK medicinal cannabis investor Sativa Investments PLC (NEX: SATI) has teamed up with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.

Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids, subject to regulatory approval.

READ: Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility

Sativa will provide the service through investee business, Canada-based Veritas Pharma Inc, and its own on-site testing facility, PhytoVista Laboratories.

Professor Clive Page OBE PhD Professor of Pharmacology at King's College London will lead the research.

"With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, Government and Regulators in their deliberations," said Sativa founder and chief executive, Jeremy Thomas.

"As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago."

Price: 4.25

Market Cap: 0

1 Year Share Price Graph



January 2019 July 2019 January 2020

Share Information

Code: SATI

Listing: NEX

Sector: **Medical technology & services**

Website: sativainvestments.co.uk

Company Synopsis:

"Sativa Group PLC is the UK's first listed medicinal cannabis company. Sativa is capitalising on its first-mover advantage and is developing a substantial UK bridgehead in what the Company believes will be a significant market in the future."

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases

where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).